Diffusion Pharmaceuticals Inc Forecasted to Post FY2019 Earnings of ($2.25) Per Share (DFFN)

Diffusion Pharmaceuticals Inc (NASDAQ:DFFN) – Investment analysts at Zacks Investment Research increased their FY2019 earnings per share (EPS) estimates for Diffusion Pharmaceuticals in a research note issued on Monday, May 13th. Zacks Investment Research analyst D. Bautz now expects that the company will post earnings of ($2.25) per share for the year, up from their previous forecast of ($2.30).

DFFN has been the topic of a number of other reports. ValuEngine cut Diffusion Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, May 1st. HC Wainwright lifted their target price on Diffusion Pharmaceuticals to $10.00 and gave the stock a “buy” rating in a report on Wednesday, March 20th.

Shares of NASDAQ DFFN opened at $4.66 on Wednesday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 5.35 and a current ratio of 5.35. The firm has a market capitalization of $14.37 million, a P/E ratio of -0.77 and a beta of 0.21. Diffusion Pharmaceuticals has a 52-week low of $1.83 and a 52-week high of $11.00.

Diffusion Pharmaceuticals (NASDAQ:DFFN) last issued its quarterly earnings results on Thursday, May 9th. The company reported ($0.81) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.90) by $0.09.

An institutional investor recently bought a new position in Diffusion Pharmaceuticals stock. Two Sigma Investments LP bought a new position in Diffusion Pharmaceuticals Inc (NASDAQ:DFFN) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 32,176 shares of the company’s stock, valued at approximately $64,000. Two Sigma Investments LP owned about 0.95% of Diffusion Pharmaceuticals as of its most recent SEC filing. Institutional investors own 5.69% of the company’s stock.

Diffusion Pharmaceuticals Company Profile

Diffusion Pharmaceuticals Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer. Its lead product candidate is transcrocetinate sodium, which has initiated Phase 3 trials for the treatment of glioblastoma multiforme (GBM); Phase 2 clinical trials for the treatment of pancreatic cancer; Phase 2/3 clinical trials for the treatment of metastatic brain cancer; and Phase 2 trial for the treatment of stroke.

Further Reading: How to track put option volume

Receive News & Ratings for Diffusion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diffusion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.